ENVERIC BIOSCIENCES INC (ENVB)

NASDAQHealth CareBiotechnologySnapshot 2026-11-04

$1.40-4.11%

Close 2026-11-05 · 1-day change

ENVERIC BIOSCIENCES INC (ENVB) Outlook: What's Priced In | QuarterlyIQ

Investment OutlookAs of Nov 4, 2026

What could strengthen or challenge ENVERIC BIOSCIENCES INC’s outlook?

The long-term thesis, the evidence coming in, and the environment around it. Thesis dated Jul 8, 2026.

Higher potential upsideImproving expectations

Next-FY EPS estimate change · 30 days

Comparable estimates unavailable

+10% or more+5%0%−5%−10% or less

Matching fiscal periods, usable estimates and at least one analyst are required.

Higher risk of downsideWeakening expectations

One observable signal. This measures changing earnings expectations, not the probability of a gain or loss.

How this is measured

The calculation requires same-period, same-provider snapshots, positive EPS, at least one analyst and a baseline within three days of the requested lookback.

Price, analyst earnings & P/E reference

The EPS and P/E reference is not available for ENVB yet.

Measure / period	Management expectations	Analyst expectations

Management figures unavailable.

Current consensus figures unavailable.

What the Thesis Depends On

Three published thesis conditions, with dated milestones shown separately.

Key Factor	Why It Matters	Current Status	Break Condition	Latest Evidence
Raise at least $2.4M via equity offerings in 2026-Q2	A primary condition in ENVERIC BIOSCIENCES INC's published investment case. The stated target is >= $2,425,000.	Intact	capital raised falls below $2.4M in 2026-Q2	Direct metric needs a verified mapping The published measure or accounting basis is not supported by an exact source binding. Date unavailableLast status assessment Nov 4, 2026Compare required operating outcomes Compare scope, accounting basis and period before treating this evidence as progress against an annual requirement.

Incoming Evidence

Compare these dated observations with the operating requirements above

Expectations trend

Same fiscal period

FY2027 · fiscal year ending 2027-12-31 · fmp

FY2027 EPS$-111.60

Outlook in Brief

The evidence, the remaining questions, and what comes next

What's improving

No recovery evidence is reported in the available driver assessments.

Still unresolved / key risks

Raise at least $2.4M via equity offerings in 2026-Q2Direct metric needs a verified mapping
Implement leadership and governance changes by mid-2026Direct metric needs a verified mapping
Reduce operating losses to about -$1.63M by 2026-Q1Published status: Broken

Next proof point

Nov 13, 2026

Look for updated results and guidance against the published targets, plus direct evidence for unresolved drivers.

Historical risk context

Observed price history; separate from operating scenarios

Price sensitivity

2.1%Typical daily move · historical

Downside history

-87.7%Maximum drawdown · trailing year

Read detailed Outlook Company context, assumptions & risks

ENVERIC BIOSCIENCES INC outlook in detail

The weekly editorial context below is a separate assessment from the dated monitor evidence above. Recovery observations do not automatically change the published thesis. Unverified outside influences are hypotheses, not measured driver evidence.

Updated Oct 31, 2026

What kind of bet this is

This is a speculative, early-stage biotech thesis, not an established earnings compounder. The thesis is in a watch state: recent performance is weak, the business is loss-making, and the latest change is a stronger sector backdrop rather than a clear improvement in company fundamentals.

What's priced into ENVERIC BIOSCIENCES INC

The evidence snapshot provides no valuation measure or explicit market expectations, so valuation cannot be judged as cheap, fair, or expensive. The muted reaction to recent developments does not establish what expectations are priced in.

What the fundamentals likely do

Near term, earnings risk is elevated, with a history of recent misses and ongoing losses and cash burn. Over the multi-year view, management is progressing preclinical work toward an IND application, the filing that would seek permission to begin clinical trials, while expanding its patent portfolio. Repeated equity funding and warrant exercises have brought in capital, but also underline the need to fund continued development.

What ENVERIC BIOSCIENCES INC hinges on

The main company-specific swing factor is whether ENVB advances EB-003 through IND-enabling studies and submits the application while maintaining access to capital. A guidance cut would add downside risk, while continued strength in major healthcare companies could support the sector backdrop. Weakening job growth could weigh on cyclical and healthcare names, though the evidence does not show how directly that would affect ENVB's development progress.

Bottom line

Over the next 1 to 3 years, ENVB's thesis rests on preclinical progress, intellectual property development, and continued funding, with high execution and earnings risks. The sector tailwind is supportive context, but the evidence does not yet show stronger company fundamentals. Not investment advice.

Development preview · refreshed Nov 5, 2026Open Living FV detail

Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.

Exact estimates & source dates

One fiscal period and provider throughout. At least five contributors are required for each plotted metric; missing coverage stays a gap. Axes show the observed range. Counts measure coverage, not revisions.

FY2027 estimate observations · fmp
Snapshot	EPS	Revenue	EPS / revenue analysts
2026-07-24	$-111.60	$15,000,000	1 / 1
2026-07-25	$-111.60	$15,000,000	1 / 1
2026-07-26	$-111.60	$15,000,000	1 / 1
2026-07-27	$-111.60	$15,000,000	1 / 1
2026-07-28	$-111.60	$15,000,000	1 / 1
2026-07-29	$-111.60	$15,000,000	1 / 1
2026-07-30	$-111.60	$15,000,000	1 / 1
2026-07-31	$-111.60	$15,000,000	1 / 1
2026-08-01	$-111.60	$15,000,000	1 / 1
2026-08-02	$-111.60	$15,000,000	1 / 1
2026-08-03	$-111.60	$15,000,000	1 / 1
2026-08-04	$-111.60	$15,000,000	1 / 1
2026-08-05	$-111.60	$15,000,000	1 / 1
2026-08-06	$-111.60	$15,000,000	1 / 1
2026-08-07	$-111.60	$15,000,000	1 / 1
2026-08-08	$-111.60	$15,000,000	1 / 1
2026-08-09	$-111.60	$15,000,000	1 / 1
2026-08-10	$-111.60	$15,000,000	1 / 1
2026-08-11	$-111.60	$15,000,000	1 / 1
2026-08-12	$-111.60	$15,000,000	1 / 1
2026-08-13	$-111.60	$15,000,000	1 / 1
2026-08-14	$-111.60	$15,000,000	1 / 1
2026-08-15	$-111.60	$15,000,000	1 / 1
2026-08-16	$-111.60	$15,000,000	1 / 1
2026-08-17	$-111.60	$15,000,000	1 / 1
2026-08-18	$-111.60	$15,000,000	1 / 1
2026-08-19	$-111.60	$15,000,000	1 / 1
2026-08-20	$-111.60	$15,000,000	1 / 1
2026-08-21	$-111.60	$15,000,000	1 / 1
2026-08-22	$-111.60	$15,000,000	1 / 1
2026-08-23	$-111.60	$15,000,000	1 / 1
2026-08-24	$-111.60	$15,000,000	1 / 1
2026-08-25	$-111.60	$15,000,000	1 / 1
2026-08-26	$-111.60	$15,000,000	1 / 1
2026-08-27	$-111.60	$15,000,000	1 / 1
2026-08-28	$-111.60	$15,000,000	1 / 1
2026-08-29	$-111.60	$15,000,000	1 / 1
2026-08-30	$-111.60	$15,000,000	1 / 1
2026-08-31	$-111.60	$15,000,000	1 / 1
2026-09-01	$-111.60	$15,000,000	1 / 1
2026-09-02	$-111.60	$15,000,000	1 / 1
2026-09-03	$-111.60	$15,000,000	1 / 1
2026-09-04	$-111.60	$15,000,000	1 / 1
2026-09-05	$-111.60	$15,000,000	1 / 1
2026-09-06	$-111.60	$15,000,000	1 / 1
2026-09-07	$-111.60	$15,000,000	1 / 1
2026-09-08	$-111.60	$15,000,000	1 / 1
2026-09-09	$-111.60	$15,000,000	1 / 1
2026-09-10	$-111.60	$15,000,000	1 / 1
2026-09-11	$-111.60	$15,000,000	1 / 1
2026-09-12	$-111.60	$15,000,000	1 / 1
2026-09-13	$-111.60	$15,000,000	1 / 1
2026-09-14	$-111.60	$15,000,000	1 / 1
2026-09-15	$-111.60	$15,000,000	1 / 1
2026-09-16	$-111.60	$15,000,000	1 / 1
2026-09-17	$-111.60	$15,000,000	1 / 1
2026-09-18	$-111.60	$15,000,000	1 / 1
2026-09-19	$-111.60	$15,000,000	1 / 1
2026-09-20	$-111.60	$15,000,000	1 / 1
2026-09-21	$-111.60	$15,000,000	1 / 1
2026-09-22	$-111.60	$15,000,000	1 / 1
2026-09-23	$-111.60	$15,000,000	1 / 1
2026-09-24	$-111.60	$15,000,000	1 / 1
2026-09-25	$-111.60	$15,000,000	1 / 1
2026-09-26	$-111.60	$15,000,000	1 / 1
2026-09-27	$-111.60	$15,000,000	1 / 1
2026-09-28	$-111.60	$15,000,000	1 / 1
2026-09-29	$-111.60	$15,000,000	1 / 1
2026-09-30	$-111.60	$15,000,000	1 / 1
2026-10-01	$-111.60	$15,000,000	1 / 1
2026-10-02	$-111.60	$15,000,000	1 / 1
2026-10-03	$-111.60	$15,000,000	1 / 1
2026-10-04	$-111.60	$15,000,000	1 / 1
2026-10-05	$-111.60	$15,000,000	1 / 1
2026-10-06	$-111.60	$15,000,000	1 / 1
2026-10-07	$-111.60	$15,000,000	1 / 1
2026-10-08	$-111.60	$15,000,000	1 / 1
2026-10-09	$-111.60	$15,000,000	1 / 1
2026-10-10	$-111.60	$15,000,000	1 / 1
2026-10-11	$-111.60	$15,000,000	1 / 1
2026-10-12	$-111.60	$15,000,000	1 / 1
2026-10-13	$-111.60	$15,000,000	1 / 1
2026-10-14	$-111.60	$15,000,000	1 / 1
2026-10-15	$-111.60	$15,000,000	1 / 1
2026-10-16	$-111.60	$15,000,000	1 / 1
2026-10-17	$-111.60	$15,000,000	1 / 1
2026-10-18	$-111.60	$15,000,000	1 / 1
2026-10-19	$-111.60	$15,000,000	1 / 1
2026-10-20	$-111.60	$15,000,000	1 / 1
2026-10-21	$-111.60	$15,000,000	1 / 1
2026-10-22	$-111.60	$15,000,000	1 / 1
2026-10-23	$-111.60	$15,000,000	1 / 1
2026-10-24	$-111.60	$15,000,000	1 / 1
2026-10-25	$-111.60	$15,000,000	1 / 1
2026-10-26	$-111.60	$15,000,000	1 / 1
2026-10-27	$-111.60	$15,000,000	1 / 1
2026-10-28	$-111.60	$15,000,000	1 / 1
2026-10-29	$-111.60	$15,000,000	1 / 1
2026-10-30	$-111.60	$15,000,000	1 / 1
2026-10-31	$-111.60	$15,000,000	1 / 1
2026-11-01	$-111.60	$15,000,000	1 / 1
2026-11-02	$-111.60	$15,000,000	1 / 1
2026-11-03	$-111.60	$15,000,000	1 / 1
2026-11-04	$-111.60	$15,000,000	1 / 1

ENVERIC BIOSCIENCES INC (ENVB)

What could strengthen or challenge ENVERIC BIOSCIENCES INC’s outlook?

Price, analyst earnings & P/E reference

What the Thesis Depends On

Incoming Evidence

Expectations trend

Outlook in Brief

What's improving

Still unresolved / key risks

Next proof point

Historical risk context

ENVERIC BIOSCIENCES INC outlook in detail

What kind of bet this is

What's priced into ENVERIC BIOSCIENCES INC

What the fundamentals likely do

What ENVERIC BIOSCIENCES INC hinges on

Bottom line

Analyst view

Price-target changes

Bottom line